AQST
NASDAQ
US
Aquestive Therapeutics, Inc. - Common Stock
$4.13
▲ +$0.00
(+0.00%)
Vol 914K
6
Quality Score
fail
Rev ✗
NI ✗
>IPO ✗
Mkt Cap
$788.1M
ROE
-21.8%
Margin
-158.8%
D/E
468.25
Beta
1.69
52W
$2–$8
Wall Street Consensus
15 analysts · Apr 20264
Strong Buy
10
Buy
1
Hold
0
Sell
0
Strong Sell
93.3%
Buy Rating
Price Chart
Similar Stocks
Earnings
Beat rate: 25.0%
Next Report
May 11, 2026
EPS Estimate: $-0.14
| Quarter | EPS Est | EPS Act | Surprise |
|---|---|---|---|
| Mar 2026 | $-0.14 | — | — |
| Dec 2025 | $-0.14 | $-0.15 | $-0.01 |
| Sep 2025 | $-0.14 | $-0.14 | $0.00 |
| Jun 2025 | $-0.17 | $-0.14 | +$0.03 |
Quarterly Revenue & Earnings
| Quarter | 2024-0… | 2024-1… | 2025-0… | 2025-0… | 2025-0… | 2025-1… |
|---|---|---|---|---|---|---|
| Revenue | — | $11.9M | $8.7M | $10.0M | $12.8M | $13.0M |
| Net Income | — | -$17.1M | -$22.9M | -$13.5M | -$15.4M | -$31.9M |
Fundamentals Trend
| Metric | 2025-06-30 | 2025-09-02 | 2025-10-02 | 2025-11-03 | 2025-12-03 | 2026-01-02 |
|---|---|---|---|---|---|---|
| ROE (TTM) | — | -21.8% | -21.8% | -21.8% | -21.8% | -21.8% |
| P/E (TTM) | — | — | — | — | — | — |
| Net Margin | -135.4% | -147.4% | -147.4% | -147.4% | -158.8% | -158.8% |
| Gross Margin | 54.4% | 61.1% | 61.1% | 61.1% | 60.3% | 60.3% |
| D/E Ratio | — | 468.25 | 468.25 | 468.25 | 468.25 | 468.25 |
| Current Ratio | 3.53 | 3.53 | 3.53 | 3.53 | 5.93 | 5.93 |
Key Ratios
ROA (TTM)
-59.9%
P/S (TTM)
18.16
P/B
15.6
EPS (TTM)
$-0.70
CF/Share
$-0.17
Rev Growth 3Y
+4.2%
52W High
$7.55
52W Low
$2.12
$2.12
52-Week Range
$7.55
Financial Health
Free Cash Flow
-$8.6M
Net Debt
-$78.7M
Cash
$121.2M
Total Debt
$42.5M
As of Dec 31, 2025
How does AQST compare to Pharmaceuticals peers?
Peer group: Micro-cap Pharmaceuticals (All) · 171 companies
AQST valuation vs Pharmaceuticals peers
P/E ratio
—
▼
0%
below
peers
(22.4)
vs Peers
vs Industry
Undervalued
P/S ratio
18.2
▲
267%
above
peers
(5.0)
vs Peers
vs Industry
Pricier
P/B ratio
15.6
▲
635%
above
peers
(2.1)
vs Peers
vs Industry
Overvalued
Div yield
—
▼
0%
below
peers
(2.0%)
vs Peers
vs Industry
Low yield
AQST profitability vs Pharmaceuticals peers
ROE
-21.8%
▲
60%
above
peers
(-54.3%)
vs Peers
vs Industry
Below avg
Net margin
-158.8%
▼
235%
below
peers
(-47.4%)
vs Peers
vs Industry
Weak
Gross margin
60.3%
▼
12%
below
peers
(68.3%)
vs Peers
vs Industry
Weak
ROA
-59.9%
▼
60%
below
peers
(-37.4%)
vs Peers
vs Industry
Weak
AQST financial health vs Pharmaceuticals peers
D/E ratio
468.3
▲
30306%
above
peers
(1.5)
vs Peers
vs Industry
High debt
Current ratio
5.9
▲
77%
above
peers
(3.4)
vs Peers
vs Industry
Below avg
Beta
1.7
▲
80%
above
peers
(0.9)
vs Peers
vs Industry
More volatile
AQST fundamentals radar
AQST
Peer median
Industry
AQST profitability vs leverage
Bubble size = market cap · X = net margin · Y = D/E ratio
AQST vs peers: key metrics
Insider Activity
NeutralBuys
0
Sells
0
TOTH A ERNEST JR
Chief Financial Officer · Mar 10
58254 shs
BARBER DANIEL R
Chief Executive Officer · Mar 10
180677 shs
BOYD PETER E
Officer · Mar 10
29814 shs
BRAENDER LORI J
Officer · Mar 10
40102 shs
JUNG CASSIE
Chief Operating Officer · Mar 10
45791 shs
KORCZYNSKI SHERRY
Officer · Mar 10
15741 shs
CIOFFI MELINA
Officer · Mar 10
25311 shs
TOTH A ERNEST JR
Chief Financial Officer · Mar 09
95000 shs
BARBER DANIEL R
Chief Executive Officer · Mar 09
262000 shs
BOYD PETER E
Officer · Mar 09
80000 shs
Last 90 days
Top Holders
Top 5: 26.51%Bratton Capital Management,…
8.04%
$39.4M
Blackrock Inc.
6.37%
$31.3M
RTW Investments LP
5.12%
$25.1M
Vanguard Group Inc
4.83%
$23.7M
EcoR1 Capital, LLC
2.15%
$10.6M
As of Dec 31, 2025
Latest News
No related news yet